NIH-funded research R01 grant

How stigma and social factors affect TB detection and care

Official title: Multi-level and Intersectional Stigma and other Social Determinant Effects on TB Case Detection, Care, and Treatment Outcomes: The MISSED TB Outcomes Study

Funded at Desmond Tutu HIV Foundation · NIH-11031416 · Data updated 2026-11-12

This project looks at how community and personal stigma and other social barriers affect whether people with TB—many living with HIV—get tested, start treatment, and complete care in South Africa.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionDesmond Tutu HIV Foundation
NIH-funded
Lab location1 site (Cape Town, South Africa)
Project startDecember 1, 2020
Project endNovember 30, 2026
Funding year2025
Award (this year)$584,233
NIH project number5R01AI150485-05
Project IDNIH-11031416 on NIH RePORTER

Who could benefit from this research

Could help

Ideal participants are household contacts of people with TB in the Cape Town study communities, especially symptomatic contacts and people living with HIV.

Less likely to help

People who do not live in the study communities, have no TB exposure, or receive care in very different health systems may not directly benefit from this specific project.

What this research studies

We will work in Cape Town communities and follow people who live with someone with TB and symptomatic household contacts who are referred for testing. You may be asked to complete surveys, take part in interviews, and be followed over time to see if you get tested, start treatment, and finish care. The team will combine household-level surveys to measure community attitudes with interviews that explore experiences of stigma and other social challenges. Researchers will link these data to clinical follow-up to find where people are being missed along the care pathway.

Why it matters

Potential benefit: If successful, the work could lead to programs that reduce stigma and other barriers so more people with TB (including those with HIV) are diagnosed early and complete treatment.

How similar studies have gone: Qualitative studies have shown stigma affects TB care, but few have measured these effects prospectively across the full care cascade, so this is a relatively new, comprehensive approach.

Where this research is happening

  • Desmond Tutu HIV Foundation
    Cape Town, South Africa
    Active

Researchers

  • Principal investigator: Medina-Marino, Andrew — Desmond Tutu HIV Foundation
  • Study coordinator: Medina-Marino, Andrew

Related research

Other NIH-funded projects on the same topics.

  • Improving access to sexual health services and PrEP for men

    This study is looking for ways to help heterosexual men aged 15-49 in South Africa better access HIV prevention methods, like PrEP, by understanding what makes it easier or harder for them to get the care they need.

    NIH research Desmond Tutu HIV Foundation · Cape Town, South Africa · NIH-10871831

  • Finding tuberculosis transmitters in communities with high TB and HIV rates

    This study is looking for people who might be spreading tuberculosis (TB) in areas where both TB and HIV are common, using a special device to safely collect and analyze tiny particles in the air, even from those who don’t have symptoms, to help us better understand how TB spreads and find ways to stop it.

    NIH research Desmond Tutu HIV Foundation · Cape Town, South Africa · NIH-10687004

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.